In our last article, we discussed how “Healthy Aging” is emerging as a new, targeted therapeutic area. Among the most surprising candidates showing promise in this field are glucagon-like peptide-1 receptor agonists (GLP-1 RAs) – medications originally developed to target diabetes. Research into GLP-1 RAs has an interesting history that started back in the early …

Continue reading “Could GLP-1 Receptor Agonists Become the First True “Longevity-Enhancing” Drugs?”